外傷性脳損傷（TBI）における改変幹細胞の研究

基本情報

NCT ID

NCT02416492

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

63

治験依頼者名

SanBio, Inc.

概要

The primary purpose of the clinical study is to evaluate the clinical efficacy of intracranial administration of SB623 cells on patients with chronic motor deficit from Traumatic Brain Injury. A secondary purpose of the study is 1) to evaluate the effect of intracranial administration of SB623 cells on disability parameters and 2) to evaluate the safety and tolerability of intracranial administration of SB623 cells. Patients with stable, chronic motor deficits secondary to focal traumatic brain injury must be 12 months post TBI.

対象疾患

介入

依頼者（Sponsor）

実施施設 (5)